Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome

Amulya A.Nageswara Rao, Grace M. Arteaga, Ann M. Reed, James M. Gloor, Vilmarie Rodriguez

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Catastrophic antiphospholipid syndrome (CAPS) is a life-threatening condition characterized by small-vessel thrombi and a rapid onset of multiorgan system failure associated with systemic inflammatory response syndrome. Current treatment options include anticoagulants, corticosteroids, plasma exchange, and intravenous immunoglobulin, but these are not always effective. Rituximab, a chimeric anti-CD20 monoclonal antibody, may help eliminate autoreactive B cells and thus limit the rapid inflammatory process involved in CAPS. We describe the use of rituximab in the successful initial management of a probable case of pediatric CAPS.

Original languageEnglish (US)
Pages (from-to)536-538
Number of pages3
JournalPediatric Blood and Cancer
Issue number4
StatePublished - Apr 2009


  • Catastrophic antiphospholipid syndrome
  • Lupus anticoagulant;rituximab; thrombosis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome'. Together they form a unique fingerprint.

Cite this